Registry, Feb 2027
every 4 weeks, intravenous
B7-H4-directed ADC · Servier (registry sponsor Day One Biopharmaceuticals)
ACC
Programs, trials, and reported response and survival for adenoid cystic carcinoma.
ACC pipeline
Programs by company or class, across phase, filing, approval, and a stop.
A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.
21 of 23 programs on this matrix
| Phase 2 | Phase 3 | Filed | Approved | Discontinued | |
|---|---|---|---|---|---|
| B7-H4-directed ADC2 programs | Registry, Feb 2027 every 4 weeks, intravenous B7-H4-directed ADC · Servier (registry sponsor Day One Biopharmaceuticals) Registry, Dec 31, 2029 Dosing n/r B7-H4-directed ADC · AstraZeneca | ||||
| CXCR1/2 inhibitor1 program | Registry, Oct 2036 Dosing n/r CXCR1/2 inhibitor · National Cancer Institute | ||||
| EGFR x MET bispecific antibody1 program | Phase 2 intravenous EGFR x MET bispecific antibody · Trisha Wise-Draper (investigator) | ||||
| gamma secretase inhibitor1 program | Phase 2 Dosing n/r gamma secretase inhibitor · Ayala Pharmaceuticals | ||||
| HDAC inhibitor1 program | Registry, Dec 31, 2028 Dosing n/r HDAC inhibitor · HitGen | ||||
| MDM2 inhibitor1 program | Phase 1/2 Dosing n/r MDM2 inhibitor · University of Michigan | ||||
| multi-kinase TKI1 program | Phase 2 oral multi-kinase TKI · Memorial Sloan Kettering (investigator) | ||||
| multi-kinase TKI with chemotherapy1 program | Registry, Jun 2028 Dosing n/r multi-kinase TKI with chemotherapy · Eye and ENT Hospital of Fudan University | ||||
| MYB mRNA degrader1 program | ENA 2026 late-breaking oral 5LBA (updated Phase 1), Nov 19, 2026 once daily, oral, once daily MYB mRNA degrader · Remix Therapeutics (merging with Passage Bio) | ||||
| Nectin-4-directed ADC1 program | Registry, Mar 2027 Dosing n/r Nectin-4-directed ADC · Memorial Sloan Kettering | ||||
| pan-NOTCH transcription inhibitor1 program | Registry, Jun 2027 oral (not re-verified) pan-NOTCH transcription inhibitor · Cellestia Biotech | ||||
| PD-1 x VEGF bispecific1 program | Registry, Jul 2027 Dosing n/r PD-1 x VEGF bispecific · Dana-Farber Cancer Institute | ||||
| PSMA radioligand1 program | Phase 2 intravenous PSMA radioligand · Radboud UMC; Johns Hopkins (investigators) | ||||
| TrkA inhibitor1 program | Registry, Dec 2027 Dosing n/r TrkA inhibitor · VM Oncology | ||||
| TROP2-directed ADC1 program | Registry, Oct 31, 2028 Dosing n/r TROP2-directed ADC · National Cancer Centre Singapore | ||||
| VEGFR multi-kinase TKI1 program | Registry, Dec 2026 once daily, oral VEGFR multi-kinase TKI · Eisai (investigator studies) | ||||
| VEGFR TKI1 program | Phase 2 twice daily, oral VEGFR TKI · Pfizer | ||||
| VEGFR/MET/TAM TKI1 program | Registry, Apr 2029 Dosing n/r VEGFR/MET/TAM TKI · Exelixis | ||||
| VEGFR2 TKI2 programs | Phase 2 Dosing n/r VEGFR2 TKI · Shanghai Ninth People's Hospital | Trials stopped once daily, oral Registry records are terminated or withdrawn. VEGFR2 TKI · Elevar Therapeutics |